@article {17438,
	title = {Low-dose IFN-alpha monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication},
	journal = {J Interferon Cytokine ResJ Interferon Cytokine ResJ Interferon Cytokine Res},
	volume = {21},
	number = {10},
	year = {2001},
	note = {Hatzakis, AGargalianos, PKiosses, VLazanas, MSypsa, VAnastassopoulou, CVigklis, VSambatakou, HBotsi, CParaskevis, DStalgis, CengClinical TrialMulticenter StudyRandomized Controlled TrialResearch Support, Non-U.S. Gov{\textquoteright}t2001/11/17 10:00J Interferon Cytokine Res. 2001 Oct;21(10):861-9. doi: 10.1089/107999001753238114.},
	month = {Oct},
	pages = {861-9},
	abstract = {To evaluate the safety and antiviral action of interferon-alpha (IFN-alpha) in HIV-1 infection, we undertook a proof of concept study in 27 treatment-naive patients. Eligible patients comprised two groups: the IFN-alphaT group (n = 17), which received 5 MIU IFN-alpha s.c. daily for 32 consecutive days, and the IFN-alphaNT group (n = 10), which did not receive IFN-alpha prior to highly active antiretroviral therapy (HAART), which was commenced on day 28 in both groups. IFN-alphaTreatment was well tolerated in 14 of the 17 patients of the IFN-alphaT group who completed the study. The mean HIV RNA reduction in the IFN-alphaT group on day 14 was 1.1 log(10). Viral load suppression was inversely associated with baseline viral load (p = 0.031). Four weeks after initiation of HAART, IFN-alphaT and IFN-alphaNT group patients had 2.40 and 1.82 log(10) HIV RNA reduction from baseline, respectively (p < 0.001). There was no evidence of cross-resistance with existing antiretrovirals in patients with HIV-RNA rebound after initial plasma viral load decline > or = 1 log(10) during IFN-alpha monotherapy. Thus, low daily IFN-alpha exhibits potent anti-HIV-1 activity in vivo without serious adverse effects. These properties render IFN-alpha an attractive candidate for further assessment as a constituent of HAART.},
	keywords = {Anti-HIV Agents/administration \& dosage/adverse effects/*therapeutic use, Antiretroviral Therapy, Highly Active, Drug Resistance, Viral, Drug Therapy, Combination, Female, HIV Infections/*drug therapy/immunology/virology, HIV-1/*drug effects/genetics/isolation \& purification, Humans, Interferon-alpha/administration \& dosage/adverse effects/*therapeutic use, Kinetics, Lymphocyte Count, Male, RNA, Viral/analysis, Treatment Outcome, Viral Load, Virus Replication/*drug effects},
	isbn = {1079-9907 (Print)1079-9907 (Linking)},
	author = {Hatzakis, A and Gargalianos, P and Kiosses, V. and Lazanas, M and Sypsa, V and Anastassopoulou, C. and Vigklis, V. and Sambatakou, H and Botsi, C. and Paraskevis, D and Stalgis, C.}
}
